Tin tức & Cập nhật

Chỉ hiển thị Multimedia
Odronextamab plus chemo safe as DLBCL treatment, with promising efficacy
Odronextamab plus chemo safe as DLBCL treatment, with promising efficacy
16 Jan 2026 bởiStephen Padilla

Combination treatment with the CD20×CD3 bispecific antibody odronextamab and chemotherapy is generally safe among previously untreated diffuse large B cell lymphoma (DLBCL) patients, without new safety signals, as shown by the results from part 1 of the phase III Olympia-3 study.

Odronextamab plus chemo safe as DLBCL treatment, with promising efficacy
16 Jan 2026
EPIK-B5 supports alpelisib plus fulvestrant for HR+, HER2– ABC
EPIK-B5 supports alpelisib plus fulvestrant for HR+, HER2– ABC
15 Jan 2026 bởiAudrey Abella

In the phase III EPIK-B5 study, adding alpelisib, an α-specific PI3K inhibitor, to fulvestrant improves progression-free survival (PFS) in men and postmenopausal women with HR+, HER2− advanced breast cancer (ABC) harbouring a PIK3CA mutation who have progressed on or after treatment with an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i).

EPIK-B5 supports alpelisib plus fulvestrant for HR+, HER2– ABC
15 Jan 2026